Erratum: Nasopharyngeal carcinoma: Molecular pathogenesis and therapeutic developments (Expert Reviews in Molecular Medicine (2007) 9:12 DOI: 10.1017/S1462399407000312);Nasopharyngeal carcinoma: Molecular pathogenesis and therapeutic developments

Expert Reviews in Molecular Medicine

Volumn 9, Issue 12, 2007, Pages 1-24

  Tao, Qian ^a,b   Chan, Anthony T C ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZACITIDINE; CETUXIMAB; CISPLATIN; DENDRITIC CELL VACCINE; FLUOROURACIL; GANCICLOVIR; ONCOPROTEIN; PROTEIN P53; THYMIDINE KINASE; TUMOR MARKER; VIRUS ANTIBODY; VIRUS VECTOR; VORINOSTAT; ZEBULARINE;

ADJUVANT THERAPY; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL TRANSPLANTATION; CLINICAL TRIAL; CYTOGENETICS; CYTOTOXIC T LYMPHOCYTE; DEMETHYLATION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EPIGENETICS; EPSTEIN BARR VIRUS; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; NASOPHARYNX CARCINOMA; ONCOGENE; PRIORITY JOURNAL; RISK FACTOR; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY; VIRUS INFECTION;

HUMAN HERPESVIRUS 4;

EID: 34548631786     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399411001864     Document Type: Erratum

References (166)

1. Vokes, E.E., Liebowitz, D.N. and Weichselbaum, R.R. (1997) Nasopharyngeal carcinoma. Lancet 350, 1087-1091
2. Yu, M.C. and Yuan, J.M. (2002) Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12, 421-429
3. Ho, J.H.C. (1990) Epidemiology of nasopharyngeal carcinoma (NPC). In Epstein-Barr Virus and Human Disease (Ablashi D.V. et al., eds), XLI-XLIV, Humana Press, Clifton, NJ, USA
4. Devi, B.C. et al. (2004) High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev 13, 482-486
5. Lee, A.W. et al. (2003) Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): An encouraging reduction in both incidence and mortality. Int J Cancer 103, 680-685
6. Jia, W.H. et al. (2006) Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer 6, 178
7. Sham, J.S.T. et al. (1990) Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet 335, 371-374
8. Cheung, F.M. et al. (2004) Nasopharyngeal intraepithelial lesion: Latent Epstein-Barr virus infection with malignant potential. Histopathology 45, 171-179
9. Pak, M.W. et al. (2002) Nasopharyngeal carcinoma in situ (NPCIS)-pathologic and clinical perspectives. Head Neck 24, 989-995
10. Pathmanathan, R. et al. (1995) Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333, 693-698
11. Marks, J.E. Phillips, J.L. and Menck, H.R. (1998) The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 83, 582-588
12. Wei, W.I. and Sham, J.S. (2005) Nasopharyngeal carcinoma. Lancet 365, 2041-2054
13. Lo, K.W., To, K.F. and Huang, D.P. (2004) Focus on nasopharyngeal carcinoma. Cancer Cell 5, 423-428
14. Young, L.S. and Rickinson, A.B. (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4, 757-768
15. Kinzler, K.W. and Vogelstein, B. (1996) Lessons from hereditary colorectal cancer. Cell 87, 159-170
16. Raab-Traub, N. (2002) Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12, 431-441
17. Tao, Q. et al. (2006) Epstein-Barr virus (EBV) and its associated human cancers - Genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 11, 2672-2713
18. Jia, W.H. et al. (2004) Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer 101, 363-369
19. Zeng, Y.X. and Jia, W.H. (2002) Familial nasopharyngeal carcinoma. Semin Cancer Biol 12, 443-450
20. Lu, S.J. et al. (1990) Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 346, 470-471
21. Hildesheim, A. et al. (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94, 1780-1789
22. Feng, B.J. et al. (2002) Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 31, 395-399
23. Xiong, W. et al. (2004) A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 64, 1972-1974
24. Mirvish, S.S. (1995) Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett 93, 17-48
25. Ho, J.H.C. (1972) Current knowledge of the epidemiology of nasopharyngeal carcinoma. In Oncogenesis and Herpesviruses (Biggs, P., de The, G. and Payne, L., eds), pp. 357-366, IARC, Lyon, France
26. Huang, D.P. et al. (1978) Carcinoma of the nasal and paranasal regions in rats fed Cantonese salted marine fish. IARC Sci Publ 315-328
27. Yu, M.C. et al. (1989) Induction of malignant nasal cavity tumours in Wistar rats fed Chinese salted fish. Br J Cancer 60, 198-201
28. Gallicchio, L. et al. (2006) Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: A systematic review. Int J Cancer 119, 1125-1135
29. Armstrong, R.W. et al. (2000) Nasopharyngeal carcinoma in Malaysian Chinese: Occupational exposures to particles, formaldehyde and heat. Int J Epidemiol 29, 991-998
30. Hildesheim, A. et al. (2001) Occupational exposure to wood, formaldehyde, and solvents and risk of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 10, 1145-1153
31. Li, W. et al. (2006) Occupational risk factors for nasopharyngeal cancer among female textile workers in Shanghai, China. Occup Environ Med 63, 39-44
32. zur Hausen, H. et al. (1970) EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-1058
33. Tao, Q. et al. (1995) Epstein-Barr-virus-infected nasopharyngeal intraepithelial lymphocytes. Lancet 345, 1309-1310
34. Tao, Q. et al. (1995) Evidence for lytic infection by Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. J Med Virol 45, 71-77
35. Nicholls, J.M. et al. (1997) The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol 183, 164-168
36. Pathmanathan, R. et al. (1995) Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 146, 1355-1367
37. Zhang, J.X. et al. (1998) Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 55, 227-233
38. Sam, C.K. et al. (1993) Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer 53, 957-962
39. Murray, P.G. et al. (1998) Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 92, 2477-2483
40. Tao, Q. et al. (1995) Epstein-Barr virus is localized in the tumour cells of nasal lymphomas of NK, T or B cell type. Int J Cancer 60, 315-320
41. Chiang, A.K. et al. (1996) Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68, 285-290
42. Cheung, S.T. et al. (1999) Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83, 121-126
43. Heussinger, N. et al. (2004) Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 203, 696-699
44. Sheng, W. et al. (2003) Malignant transformation of Epstein-Barr virus-negative Akata cells by introduction of the BARF1 gene carried by Epstein-Barr virus. J Virol 77, 3859-3865
45. Chen, H.L. et al. (1992) Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells. Virology 191, 193-201
46. Decaussin, G. et al. (2000) Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 60, 5584-5588
47. Cochet, C. et al. (1993) Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 197, 358-365
48. Huang, D.P. et al. (1991) Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma. Cancer Genet Cytogenet 54, 91-99
49. Huang, D.P. et al. (1989) Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese. Int J Cancer 43, 936-939
50. Wong, N. et al. (2003) Molecular cytogenetic characterization of nasopharyngeal carcinoma cell lines and xenografts by comparative genomic hybridization and spectral karyotyping. Cancer Genet Cytogenet 140, 124-132
51. Lo, K.W. et al. (2000) High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 60, 3348-3353
52. Huang, D.P. et al. (1994) A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res 54, 4003-4006
53. Huang, Z. et al. (2004) Construction of tree models for pathogenesis of nasopharyngeal carcinoma. Genes Chromosomes Cancer 40, 307-315
54. Hui, A.B. et al. (2002) Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol 20, 467-473
55. Guo, X. et al. (2002) Identifying cancer-related genes in nasopharyngeal carcinoma cell lines using DNA and mRNA expression profiling analyses. Int J Oncol 21, 1197-1204
56. Rodriguez, S. et al. (2005) Conventional and array-based comparative genomic hybridization analysis of nasopharyngeal carcinomas from the Mediterranean area. Cancer Genet Cytogenet 157, 140-147
57. Hui, A.B. et al. (2005) Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 65, 8125-8133
58. Hurst, C.D. et al. (2004) High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 23, 2250-2263
59. Seng, T.J. et al. (2007) The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 26, 934-944
60. Ying, J. et al. (2006) Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia 20, 1173-1175
61. Ying, J. et al. (2006) Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25, 1070-1080
62. Effert, P. et al. (1992) Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 66, 3768-3775
63. Sun, Y., Hegamyer G. and Colburn, N.H. (1993) Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. Oncogene 8, 791-795
64. Lo, K.W. et al. (1996) Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56, 2721-2725
65. Kwong, J. et al. (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8, 131-137
66. Lo, K.W. et al. (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61, 3877-3881
67. Qiu, G.H. et al. (2004) The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3 is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 23, 4793-4806
68. Chow, L.S. et al. (2004) RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer 109, 839-847
69. Ying, J. et al. (2005) The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 11, 6442-6449
70. Lung, H.L. et al. (2004) Fine mapping of the 11q22-23 tumor suppressive region and involvement of TSLC1 in nasopharyngeal carcinoma. Int J Cancer 112, 628-635
71. Kwong, J. et al. (2007) Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer 46, 171-180
72. Chan, S.L. et al. (2007) The tumor suppressor Wnt inhibitory factor 1 (WIF1) is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest, Mar 26 [Epub ahead of print]
73. Henle, G. and Henle, W. (1976) Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17, 1-7
74. Chan, A.T. et al. (2002) Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94, 1614-1619
75. Lo, Y.M. et al. (2000) Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60, 6878-6881
76. Tune, C.E. et al. (1999) Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. J Natl Cancer Inst 91, 796-800
77. Stevens, S.J. et al. (2006) Noninvasive diagnosis of nasopharyngeal carcinoma: Nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 119, 608-614
78. Tong, J.H. et al. (2002) Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res 8, 2612-2619
79. Lee, N. et al. (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys 53, 12-22
80. Kam, M.K et al. (2004) Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. Int J Radiat Oncol Biol Phys 60, 1440-1450
81. Rossi, A. et al. (1988) Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study. J Clin Oncol 6, 1401-1410
82. Chart, A.T. et al. (1995) A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33, 569-577
83. International Nasopharynx Cancer Study Group. VUMCA I trial (1996) Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 35, 463-469
84. Chua, D.T. et al. (1998) Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 83, 2270-2283
85. Al-Sarraf, M. et al. (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16, 1310-1317
86. Al-Sarraf, M. et al. (2001) Superiority of five year survival with chemo-radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer NPC Intergroup 0099. Proc ASCO 20, 905 (Abstract)
87. Ma, J. et al. (2001) Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherany alone in patiets with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19, 1350-1357
88. Chi K.H. et al. (2002) A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 52, 1238-1244
89. Chan, A.T. et al. (2002) Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20, 2038-2044
90. Chan, A.T. et al. (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97, 536-539
91. Lin, J.C. et al. (2003) Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21, 631-637
92. Kwong, D.L. et al. (2004) Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: A factorial study. J Clin Oncol 22, 2643-2653
93. Wee, J. et al. (2005) Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23, 6730-6738
94. Lee, A.W. et al. (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23, 6966-6975
95. Baujat, B. et al. (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64, 47-56
96. Hui, E.P. et al. (2004) Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 101, 300-306
97. Ma, B.B. and Chan, A.T. (2006) Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev Anticancer Ther 6, 383-394
98. Chan, A.T. et al. (2005) Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23, 3568-3576
99. Rooney, C.M. et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345, 9-13
100. Papadopoulos, E.B. et al. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 33, 1185-1191
101. Khanna, R. et al. (1999) Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 96, 10391-10396
102. Chua, D. et al. (2001) Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 94, 73-80
103. Comoli, P. et al. (2004) Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts. LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 15, 113-117
104. Comoli, P. et al. (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23, 8942-8949
105. Straathof, K.C. et al. (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105, 1898-1904
106. Lin, C.L. et al. (2002) Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 62, 6952-6958
107. Taylor, G.S. et al. (2004) Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: Potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 78, 768-778
108. Ambinder, R.F., Robertson, K.D. and Tao, Q. (1999) DNA methylation and the Epstein-Barr virus. Semin Cancer Biol 9, 369-375
109. Tao, Q. and Robertson, K.D. (2003) Stealth technology: How Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 109, 53-63
110. Moore, S.M. et al. (2001) Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 45, 2082-2091
111. Westphal, E.M. et al. (2000) Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: A potential method for treating EBV-positive malignancies. Cancer Res 60, 5781-5788
112. Cheng, J.C. et al. (2004) Preferential response of cancer cells to zebularine. Cancer Cell 6, 151-158
113. Abele, R. et al. (1987) The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 23, 1921-1924
114. van Groeningen, C.J. et al. (1986) Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46, 4831-4836
115. Chan, A.T. et al. (2004) Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 22, 1373-1381
116. Franken, M. et al. (1996) Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Nat Med 2, 1379-1382
117. Li, J.H. et al. (2002) Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res 62, 171-178
118. Chia, M.C. et al. (2004) A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy. Mol Ther 9, 804-817
119. Delecluse, H.J. and Hammerschmidt, W. (2000) The genetic approach to the Epstein-Barr virus: From basic virology to gene therapy. Mol Pathol 53, 270-279
120. Ambinder, R.F. et al. (1996) Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin Cancer Biol 7, 217-226
121. Minna, J.D., Roth, J.A. and Gazdar, A.F. (2002) Focus on lung cancer. Cancer Cell 1, 49-52,
122. Fries, K.L., Miller, W.E. and Raab-Traub, N. (1996) Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 70, 8653-8659
123. Codd, J.D. et al. (1999) A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma. J Pathol 187, 549-555
124. Sheu, L.F. et al. (1997) Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia, and nasopharyngeal carcinoma: Association with p53 expression. Hum Pathol 28, 556-562
125. Yu, Y. et al. (2003) Significance of c-Myc and Bcl-2 protein expression in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 129, 1322-1326
126. Lu, Q.L. et al. (1993) Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 53, 29-35
127. Lai, J.P. et al. (2002) Association between high initial tissue levels of cyclin d1 and recurrence of nasopharyngeal carcinoma. Laryngoscope 112, 402-408
128. Xie, L. et al. (2000) Identification of differentially expressed genes in nasopharyngeal carcinoma by means of the Atlas human cancer cDNA expression array. J Cancer Res Clin Oncol 126, 400-406
129. Chu, W.K. et al. (2006) Dual regulation of the DeltaNp63 transcriptional activity by DeltaNp63 in human nasopharyngeal carcinoma cell. Biochem Biophys Res Commun 342, 1356-1360
130. Crook, T. et al. (2000) High level expression of deltaN-p63: A mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 19, 3439-3444
131. Guo, C. et al. (2006) The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection. J Transl Med 4, 23
132. Miller, W.E., Earp, H.S. and Raab-Traub, N. (1995) The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 69, 4390-4398
133. Ma, B.B. et al. (2003) Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck 25, 864-872
134. Leong, J.L. et al. (2004) Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 114, 153-157
135. Yazici, H. et al. (2000) c-erbB-2 gene amplification in nasopharyngeal carcinoma. Cancer Invest 18, 6-10
136. Yung, W.C. et al. (1995) Ras mutations are uncommon in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 31B, 399-400
137. Porter, M.J. et al. (1994) The detection of the c-myc and ras oncogenes in nasopharyngeal carcinoma by immunohistochemistry. Acta Otolaryngol 114, 105-109
138. Cheung, H.W. et al. (2004) Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 25, 881-887
139. Fan, C.S. et al. (2000) Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol 31, 169-178
140. Wu, H.C. et al. (2004) MDM2 expression in EBV-infected nasopharyngeal carcinoma cells. Lab Invest 84, 1547-1556
141. Qian, W. et al. (1995) Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 31B, 328-332
142. Qian, C.N. et al. (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62, 589-596
143. Horikawa, T. et al. (2001) Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 159, 27-33
144. Or, Y.Y. et al. (2005) Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. Int J Oncol 26, 49-56
145. Fang, Y. et al. (2001) Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer 30, 254-260
146. Liu, X.Q. et al. (2003) Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p2l.3, in human nasopharyngeal carcinoma. Int J Cancer 106, 60-65
147. Zhou, J. et al. (2004) BRD7, a novel bromodomain gene, inhibits G1-S progression by transcriptionally regulating some important molecules involved in ras/MEK/ERK and Rb/E2F pathways. J Cell Physiol 200, 89-98
148. Wong, T.S. et al. (2003) Differential gene methylation in undifferentiated nasopharyngeal carcinoma. Int J Oncol 22, 869-874
149. Wong, T.S. et al. (2004) Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 10, 2401-2406
150. Chang, H.W. et al. (2003) Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int J Cancer 105, 851-855
151. Tsao, S.W. et al. (2003) The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. Eur J Cancer 39, 524-531
152. Baba, Y. et al. (2001) Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma. Cancer Detect Prev 25, 414-419
153. Cheung, H.W. et al. (2005) Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol Carcinog 43, 237-245
154. Lo, K.W. et al. (2002) Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 98, 651-655
155. Ko, J.Y. et al. (2002) Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma. Cancer 94, 1987-1996
156. Ng, A. et al. (2003) Regulation of the H19 imprinting gene expression in human nasopharyngeal carcinoma by methylation. Int J Cancer 104, 179-187
157. Chang, H.W. et al. (2003) Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient. Clin Cancer Res 9, 1033-1038
158. Kwong, J. et al. (2005) Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int J Cancer 113, 386-392
159. Chow, L.S. et al. (2004) Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 12, 781-787
160. Claudio, P.P. et al. (2000) Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. Cancer Res 60, 8-12
161. Wong, T.S. etal. (2003) Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma. Clin Cancer Res 9, 3042-3046
162. Lung, H.L. et al. (2005) THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma, Oncogene 24, 6525-6532
163. Spruck, C.H. (1992) Absence of p58 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 52, 4787-4790
164. Sun, Y. et al. (1992) An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 89, 6516-6520
165. Cai, X. et al. (2006) Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2(3), e23
166. Pfeffer, S. (2004) Identification of virus-encoded microRNAs. Science 304, 734-736